<DOC>
	<DOCNO>NCT00624728</DOCNO>
	<brief_summary>18F-Fluorothymidine recently develop PET tracer image tumor cell proliferation . Very data report interest use tracer cerebral malignant tumor management . In project , want compare tumoral volume obtain PET MRI , gold standard histopathological diagnosis accord WHO grade malignancy scale Ki-67 proliferation index , preoperative evaluation much tumoral postoperative residue evaluation . Furthermore , want explore interest 18F-FLT-PET volume well delineate tumoral volume radiotherapeutic management glioma .</brief_summary>
	<brief_title>Assessment 18FLT PET-CT Volume Definition High-grade Gliomas ( GLIO-TEP )</brief_title>
	<detailed_description>- Background : 18FDG widely use tracer oncologic positron emission tomography ( PET ) . However , high glucose utilization normal gray matter limit utility brain exploration . More recently , 18FLT introduce PET tracer tumor imaging . It find useful non-invasive assessment proliferation status various tumor . Its potential clinical use evaluation brain tumor clearly determine sparse study . - The primary objective study assess positive predictive value PET-CT uptake 18FLT diagnose malignant tissue comparison histopathological gold standard diagnosis accord WHO grade malignancy scale Ki-67 proliferation index , time preoperative evaluation . - Secondary objective : describe compare preoperative tumor volume postoperative residual tumor volume assess 18FLT PET-CT MRI , describe quantitative proliferation index PET ( SUV `` standardize uptake value '' ) . - Study design : This exploratory cross-sectional study two separate time : pre-and postoperative . Eligible patient include consecutively . Histological sample analyze blindly image data . Assessments PET-CT MRI volume blind . - Procedure : After information write informed consent surgery , patient undergo MRI 18F-FLT PET-CT obtain tumor volume accord modality . Then , surgeon make different biopsy ) area MR abnormality FLT uptake , ii ) area FLT uptake MR abnormality ( surgery approach way functional area ) , iii ) area MR abnormality without FLT uptake , iiii ) area without uptake biopsy possible area surgery approach way . Then , sample blindly analyze determine Ki-67 proliferation index WHO grade malignancy scale . Patients undergo 18F-FLT PET-TDM MRI least 4 week surgery , week precede radiotherapy , determine residual tumor volume .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<criteria>patient 18 suspicion malignant glioma MRI aspect surgical indication neuronavigation sign informed consent absence contraindication MRI absence pregnancy breastfeed woman : pregnancy breastfeed oral intrauterine contraception ( postmenopause ) secondary exclusion high grade glioma diagnostic ( glioblastoma astrocytoma grade III ) confirm surgery histopathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>Alovudine [ Substance Name ]</keyword>
	<keyword>18F-FLT</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Glioblastoma</keyword>
</DOC>